RIYAD F. ALZHRANI1, LAMA BINOBAID2, ABDULAZIZ A. ALORAINI1, MESHAL S. ALSAHLI1, AHMED H. BAKHEIT3, HANADI H. ASIRI3, SABRY M. ATTIA2, ALI ALHOSHANI2, GAMALELDIN I. HARISA1,*
Oncology Research, Vol.33, No.4, pp. 919-935, 2025, DOI:10.32604/or.2024.054537
- 19 March 2025
Abstract Objective: Prostate cancer (PCA) is the second most widespread cancer among men globally, with a rising mortality rate. Enzyme-responsive lipid nanoparticles (ERLNs) are promising vectors for the selective delivery of anticancer agents to tumor cells. The goal of this study is to fabricate ERLNs for dual delivery of gefitinib (GF) and simvastatin (SV) to PCA cells. Methods: ERLNs loaded with GF and SV (ERLNGFSV) were assembled using bottom-up and top-down techniques. Subsequently, these ERLN cargoes were coated with triacylglycerol, and phospholipids and capped with chitosan (CS). The ERLNGFSV, and CS engineered ERLNGFSV (CERLNGFSV) formulations were… More >
Graphic Abstract
Login
Register
